We are pleased to share that the Brazilian Health Regulatory Agency (ANVISA) has renewed the accreditation for Lambda Therapeutic Research facilities in Ahmedabad and Mehsana. The renewed validity extends through November 2027.

This renewal reflects the consistent operational quality maintained at both sites and supports clinical research aligned with international regulatory expectations. We also recognise the steady efforts of our teams across functions who help maintain these standards and ensure continued compliance.

As a full-service global CRO, Lambda Therapeutic Research provides comprehensive clinical research services for pharmaceutical, biotech, and generic organisations worldwide. For more information about our capabilities or facility accreditations, please contact bd@lambda-cro.com.